Oliver FitzGerald outlines his highlights from the psoriatic arthritis presentations at the EULAR 2020 E-Congress, and discusses what the study results mean for clinical practice (10:13).
Kim Lauper discusses findings from the JAKPOT study, an international collaboration showing comparable JAK inhibitor and TNF inhibitor retention rates in real-world patients with rheumatoid arthritis (3:50).
Alexis Ogdie comments on the results of two phase 3 trials demonstrating the potential of upadacitinib as a treatment option for psoriatic arthritis patients with and without prior exposure to biologic agents (3:59).
John Isaacs comments on two studies on venous thromboembolism in patients with rheumatoid arthritis, highlighting the robustness of the findings and what they mean for patient management (5:47).
03-06-2020 | EULAR 2020 | Conference coverage | Video